Roche to end DIAN-TU-001 study for rare Autosomnal dominant Alzheimer's disease

10 February 2020 – Roche announces discontinuation of part of phase 2/3 study for people with early onset Autosomal dominant Alzheimer's disease. [read more]

Global Perspective Newsletter for December 2019

10 December 2019 - The December 2019 edition of our Global Perspective Newsletter is now available. Read the latest news from ADI, our partners and member associations, including updates on the upcoming World Alzheimer's Month, World Alzheimer Report, and much more. [read more]

ADI and DAI invite you to a joint webinar on dementia and rights

11 December 2019 – ADI is happy to announce that we will be hosting a joint webinar, Dementia & rights; from principles to practice, with Dementia Alliance International (DAI) on 27 February 2020. [read more]

China approves first drug for mild to moderate Alzheimer's in 17 years

4 November 2019 – Chinese Pharmaceutical Company Green Valley announced over the weekend that their drug Oligomannate (GV-971) has been granted conditional approval by the National Medical Products Administration (NMPA) as a new drug for the treatment of “mild to moderate Alzheimer's disease and improving cognitive function”. [read more]

Syndicate content